ReviewDialogues in clinical neuroscience2010
Drug treatment of obsessive-compulsive disorder.
Review in Dialogues in clinical neuroscience, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 147 citations in OpenAlex.
- Memantine for the treatment of obsessive-compulsive disorder: a systematic review and narrative synthesis.BMC psychiatry · 2026Pooled it
- Economic Analyses of Obsessive-Compulsive Disorder Interventions: A Systematic Review.PharmacoEconomics · 2023Pooled it
- Side-effects of SSRIs disrupt multimodal treatment for pediatric OCD in a randomized-controlled trial.Journal of psychiatric research · 2015Trial
- Targeting of Itch by clomipramine or gene therapy improves cognitive defects related to Alzheimer's disease.iScience · 2026Article
- Analyzing the Contents of a Large, Public Online Peer Support Forum for Obsessive-Compulsive Disorder: Thematic Analysis.JMIR formative research · 2025Article
- Hereditary Patterns and Genetic Associations in Obsessive-Compulsive Disorder (OCD): Neuropsychiatric Insights, Genetic Influences, and Treatment Perspectives.Current gene therapy · 2025Review
- Article
- Obsessive-compulsive disorder, major depressive disorder, and addiction: the vicious relationship.European journal of translational myology · 2024Article
- Cross-EHR validation of antidepressant response algorithm and links with genetics of psychiatric traits.medRxiv : the preprint server for health sciences · 2024Article
- Article
- Microbial Reprogramming in Obsessive-Compulsive Disorders: A Review of Gut-Brain Communication and Emerging Evidence.International journal of molecular sciences · 2023Review
- Olfactory Obsessions: A Study of Prevalence and Phenomenology in the Course of Obsessive-Compulsive Disorder.Journal of clinical medicine · 2023Article
- Examining the Use of Antidepressants for Adolescents with Depression/Anxiety Who Regularly Use Cannabis: A Narrative Review.International journal of environmental research and public health · 2022Review
- Adjunct Triptorelin in the Treatment of Obsessive-Compulsive Disorder in Clients Receiving Selective Serotonin Reuptake Inhibitors (SSRIs).Iranian journal of psychiatry · 2021Article
- Psychopharmacological Treatment, Intraocular Pressure and the Risk of Glaucoma: A Review of Literature.Journal of clinical medicine · 2021Review
- Bidirectional Behavioral Selection in Mice: A Novel Pre-clinical Approach to Examining Compulsivity.Frontiers in psychiatry · 2021Review
- Help-Seeking Intention in Obsessive-Compulsive Disorder: Predictors and Barriers in South Africa.Frontiers in psychiatry · 2021Article
- Defining data-driven subgroups of obsessive-compulsive disorder with different treatment responses based on resting-state functional connectivity.Translational psychiatry · 2020Article
- The Effect of Orexin Receptor Antagonism on Quinpirole-Induced Compulsive-Like Checking Behavior in Rats.Neurotoxicity research · 2020Article
- Efficacy of nicotine administration on obsessions and compulsions in OCD: a systematic review.Annals of general psychiatry · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Knowledge of pharmacotherapeutic treatment options in obsessive-compulsive disorder (OCD) has grown considerably over the past 40 years. Serotonergic antidepressants, such as selective serotonin reuptake inhibitors (SSRls) and clomipramine, are the established pharmacologic first-line treatment of OCD. Medium to large dosages and acute treatment for at least 3 months are recommended until efficacy is assessed. In case of significant improvement, maintenance treatment is necessary, Unfortunately, about half of the patients do not respond sufficiently to oral serotonergic antidepressants; augmentation with atypical antipsychotics is an established second-line drug treatment strategy. Alternatives include intravenous serotonergic antidepressants and combination with or switch to cognitive behavioral psychotherapy. Remarkably, a considerable proportion of OCD patients still do not receive rational drug treatment. Novel research approaches, such as preliminary treatment studies with glutamatergic substances, and trials with further drugs, as well as needed aspects of future research, are reviewed.
Indexed as
Identifiers
20623923PMC3181958W193306346What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.